Фузидовая кислота в современной клинической практике | КМАХ

Фузидовая кислота в современной клинической практике

Клиническая Микробиология и Антимикробная Химиотерапия. 2001; 3(4):324-338

​ Белькова Ю.А.
фузидовая кислота антибиотикотерапия антибиотикорезистентность S.aureus MRSA
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2001; 3(4):324-338

Аннотация

Широкое распространение множественно-резистентных грам(+) возбудителей, особенно метициллинорезистентных стафилококков, заставляет пересмотреть отношение к такому «старому» препарату, как фузидовая кислота, и обратить внимание на возможность ее применения в терапии инфекций, вызванных этими микроорганизмами. В обзоре литературы представлены сведения о химических и физических свойствах, антимикробной активности, механизме действия, фармакокинетике, показаниях к применению и клинической эффективности фузидовой кислоты, а также о спектре возможных нежелательных лекарственных реакций. Фармакологический профиль фузидовой кислоты, хорошая переносимость, низкий уровень резистентности и отсутствие перекрестной резистентности с другими антибиотиками, а также возможность ступенчатой терапии позволяют рекомендовать этот препарат к более широкому применению, особенно при инфекциях, вызванных Staphylococcus аureus, в том числе и метициллинорезистентными штаммами.

  • 1. Reynolds J.I.F., editor. Martindall The Extra Pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society; 1996. p. 233-5.
  • 2. Von Daehne W., Godtfredsen W.O., Rasmussen P.R. Structure-activity relationships in fusidic acid-type antibiotics. Adv Appl Microbiol 1979; 25:95-146.
  • 3. Henriksen A.S., Duvold T. New potent analogues of fusidic acid. Clin Microbiol Infect 2001; 7 (Suppl 1):458.
  • 4. Cundliffe E. The mode of action of fusidic acid. Biochem Biophys Res Commun 1972; 46:1794-801.
  • 5. Mazumder R. Sites of action of fusidic acid in eukaryotes; inhibition by fusidic acid of a ribosome-independent GTPase from Artemia salina embryos. Eur J Biochem 1975; 58:549-54.
  • 6. Otaka T., Kaji A. Evidence that fusidic acid inhibits the binding of aminoacyl-tRNA to the donor as well as the acceptor site of the ribosomes. Eur J Biochem 1973; 38:46-53.
  • 7. Perry M.J., Hendricks-Gittins A., Stacey L.M., Adlard M.W., Noble W.C. Fusidan antibiotics produced by dermatophytes. J Antibiot (Tokyo) 1983; 36:1659-63.
  • 8. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990; 25 (Suppl B):1-5.
  • 9. Kanazaki H., Akiyama H., Kanamoto A., et al. Outbreak of fusidic acid resistant Staphylococcos aureus. Nippon Hifuca Gakkai Zasshi 1989; 99:507-10.
  • 10. Drugeon H.B., Caillon J., Juvin M.E. In vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcos aureus. J Antimicrob Chemother 1994; 34:899-907.
  • 11. Pohlod D.J., Saravolatz L.D., Somerville M.M. In-vitro susceptibility of Gram-positive cocci to LY146032 teicoplanin; sodium fusidate; vancomycin; and rifampicin. J Antimicrob Chemother 1987; 20:197-202.
  • 12. Dixson S., Brunfitt W., Hamilton-Miller J.M. in vitro activity of six antibiotics against multiresistant staphylococci and other Gram-positive cocci. Eur J Clin Microbiol 1985; 4:19-23.
  • 13. Maple P.A.C., Hamilton-Miller J.M.T., Brunfitt W. World-wide antibiotic resistans in methicilin-resistant Staphylococcos aureus. Lancet 1989; 1:537-40.
  • 14. Toma E., Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for Gram-positive cocci. J Clin Microbiol 1995; 33:1712-5.
  • 15. Coutant C., Olden D., Bell J., Turnidge J.D. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of the staphylococci by the NCCLS method. Diagn Microbiol Infect Dis 1996; 25:9-13.
  • 16. Hart A.P., McColl K., Thomas C., Orr N.A. Performance profiles of topical antimicrobials in vitro. J Appl Bacteriol 1989; 67:317-27.
  • 17. Barber M., Waterworth P.M. Antibacterial activity in vitro of Fucidin. Lancet 1962; 1:931-2.
  • 18. Freeman C., Robinson A., Cooper B., Mazens-Sullivan M., Quintiliani R., Nightingale C. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995; 21:47-50.
  • 19. Heczko P.B., Kasprowicz A., Pulverer G. Susceptibility of human skin aerobic diphtheroids to antimicrobial agents in vitro. Antimicrob Chemother 1977; 3:141-6.
  • 20. Black W.A., McNellis D.A. Susceptibility of Nocardia specis to modern antimicrobial agents. Antimicrob Agents Chemother 1970; 10:346-9.
  • 21. Nasher M.A., Hay R.G., Mahgoub E.S., Gumaa S.A. in vitro studies of antibiotic sensitivities of Streptomyces somaliensis – a case of human actinimycetoma. Trans R Soc Trop Med Hyg 1989; 83:265-8.
  • 22. Bannatyne R.M., Cheung R. Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981. Antimicrob Agents Chemother 1982; 21:666-7.
  • 23. Friis-Moller A., Rechnitzer C., Nielsen L., Madsen S. Treatment of Legionella lung abscess with erythromycin and fusidic acid (letter). Eur J Clin Microbiol 1990; 4:513-5.
  • 24. Van Caekenberghe D. Comparative in vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. J Antimicrob Chemother 1990; 26:381-6.
  • 25. Franzblau S.G., Biswas A.N., Harris E.B. Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae. Antimicrob Agents Chemother 1992; 36:92-4.
  • 26. Hoffner S.E., Olsson-Liljequist B., Rydgard K.J., Svenson S.B., Kallenius G. Susceptibility of mycobacteria to fusidic acid. Eur J Clin Microbiol Infect Dis 1990; 9:294-7.
  • 27. Steinkraus G.E., McCarthy L.R. in vitro activity of sodium fusidate against anaerobic bacteria. Antimicrob Agents Chemother 1979; 16:120-2.
  • 28. Hassan H., O’Hare M.D., Felmingham D. in vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria. Singapore Med J 1990; 31:56-8.
  • 29. Spiekermann C. in vitro sensitivity of Actinomyces israelii, Actinobacillus actinomycetem-comitans and Bacteroides melaninogenicus to cephalothin, cephaloridin, gentamicin, fusidic acid and licomycin. Int Z klin Pharmakol Ther Toxikol 1970; 3:318-20.
  • 30. Canzi A.M., Weber P., Boussougant Y. Activity of fusidic acid on strictly anaerobic bacteria. Pathol Biol (Paris) 1987; 35:577-80.
  • 31. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12:59-66.
  • 32. Bendtzen K., Diamant M., Faber V. Fusidic acid, an immunosupressive drug with functions similar to cyclosporin A. Cytokine 1990; 2:423-9.
  • 33. Nicoletti F., Zaccone P., Di Marco R., et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 1995; 85:645-50.
  • 34. Forsgren A., Schemling D., Banck G. Effects of antibiotics on chemotaxis of human polymorphonuclear leucocytes in vitro. Infection 1978; 6 (Suppl 1):102-6.
  • 35. Langholz E., Brynskov J., Freund L.G., Bendtzen K. Fusidic acid for Behcet’s colitis: a novel approach to T-cell specific immunosuppressive therapy. Dan Med Bull 1991; 38:284.
  • 36. Langholz E., Brynskov J., Bendtzen K., Vilien M., Binder V. Treatment of Crohn’s disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Therapeut 1992; 6:495-502.
  • 37. Rubisz-Brzezinska J., Zebracka T., Mozdzanowska K., Mozdzanowski J. Treatment of systemic scleroderma with fucidin in relation to clinical evaluation and analysis to free amino acids in the serum. Przegl Dermatol 1986; 73:305-11.
  • 38. Nicoletti F., Meroni P.L., Lunetta M., et al. Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet 1991; 337:1292.
  • 39. Faber V., Dalgleish A.G., Newell A., Malkovsky M. Inhibition of HIV replication in vitro by fusidic acid. Lancet 1987; 2:827-88.
  • 40. Hording M., Christensen K.C., Faber V. Fusidic acid treatment of HIV infection: no significant effect in a pilot trial. Scand J Infect Dis 1990; 22:649-52.
  • 41. Richter Dahlfors A.A., Kurland C.G. Novel mutants of elongation factor G. J Mol Biol 1990; 20:549-57.
  • 42. Lacey R.W., Rosdahl V.T. An unusual jpenicillinase plasmid of Staphylococcos aureus; evidence for its transfer under natural conditions. J Med Microbiol 1974; 7:117-25.
  • 43. Lacey R.W., Grinstead J. Linkage of fusidic acid resistance to penicillinase plasmid in Staphylococcos aureus. J Gen Microbiol 1974; 83:375-87.
  • 44. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl 2):35-44.
  • 45. Сидоренко С.В., Резван С.П., Грудинина С.А., Кротова Л.А., Стерхова Г.В. Результаты многоцентрового исследования чувствительности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиот химиотер 1998; 43 (7):15-25.
  • 46. Murray I.A., Cann P.A., Day P.J., et al. Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol 1995; 254:993-1005.
  • 47. Von der Haar B., Rosenberg D., Dittrich W., Schrempf H. Inactivation of fusidic acid by resistant Streptomyces strains. Antibiot (Tokyo) 1991; 44:785-92.
  • 48. Faber M., Rosdahl V.T. Susceptibility of fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother 1990; 25:7-14.
  • 49. Turnidge J.D., Nimmo G.R., Francis G. Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Med J Aust 1996; 164:68-71.
  • 50. Roser H. Determination of resistance to the antibiotic staphylomycin. Med Klin 1966; 61:919-21.
  • 51. Statement 1996 CA-SFM Zone sizes and MIC breackpoints for non-fastidious organisms. Clin Microbiol Infect 1996; 2 (Suppl 1):46-49.
  • 52. Mandell L.A. In: Mandell G.L., Bennett J.E., Raphael D., editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston; 2000. p. 306-7.
  • 53. Huebner J., Kropec A., Engels I., Daschner F. in vitro susceptibility of methicillin-resistant Staphylococcos aureus and slime-producing and non-slime-producing coagulase-negative staphylococci to fusidic acid. Chemotherapy 1992; 38:206-10.
  • 54. Evans R.J., Waterworth P.M. Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances. J Clin Pathol 1966; 19:555-60.
  • 55. Taburet A.M., Guibert J., Kitzis M.D., Sorensen H. Acar J.F., Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of new formulation. J Antimicrob Chemother 1990; 25 (Suppl B):23-31.
  • 56. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12 (Suppl 2):23-34.
  • 57. Vaillant L., Machet L., Taburet A.M., Sorensen H., Lorette G. Levels of fusidic acid in skin blister fluid and serum after repeated administration of two doses (250 and 500 mg). Br J Dermatol 1992; 126:591-5.
  • 58. Godtfredsen W.O., Vangedal S. On the metabolism of fusidic acid in man. Acta Chem Scand 1966; 20:1599-607.
  • 59. Wise R., Pippard M., Mitchard M. The disposition of sodium fusidate in man. Br J Clin Pharmacol 1977; 4:615-9.
  • 60. Reeves D.S. The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987; 20:467-76.
  • 61. Peter J.D., Jehl F., Pottecher T., Dupeyron J.P., Monteil H. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob Agents Chemother 1993; 37:501-6.
  • 62. Brown N.M., Reeves D.S., McMullin C.M. The pharmacokinetics and protein binding of patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1997; 39:803-9.
  • 63. Robert P.Y., Adenis J.P. Comparative review of topical ophthalmic antibacterial preparations. Drugs 2001; 61 (Suppl 2):175-85.
  • 64. Carr W.D., Wall A.R., Georgala-Zervogiani S., Stratigos J., Gouriotou K. Fusidic acid tablets in patients with skin and soft-tissue infection: A dose-finding study. Eur J Clin Res 1994; 5:87-95.
  • 65. Machet L., Puissant A., Vaillant L., et al. Treatment of skin infections with two dosages of fusidic acid (500 mg/day and 1 g/day) compared with pristinamycin 2 g/day: A multicenter randonmised study. Nouvelles Dermatol 1994; 13:520-4.
  • 66. Eykyn S.J. Staphylococcal bacteremia and endocarditis and fusidic acid. J Antimicrob Chemother 1990; 25 (Suppl B):33-8.
  • 67. Leibowitz G., Golan D., Yeshurun D., Brezis M. Leukopenia and thrombocytopenia due to fusidic acid (letter). Postgrad Med J 1991; 67:591-2.
  • 68. Lewis F.M., Gawkrodger D.J., Bleehen S.S., Nelson M.E. Multiple contact sensitivity to eye drops. Contact Dermatitis 1993; 28:246-7.
  • 69. Johns W.H., Bates T.R. Drug-cholestyramine interactions. II. Influence of cholestyramine on GI absorption of sodium fusidate. J Pharm Sci 1972; 61:735-9.
  • 70. Fosse T., Appert A., Delpech D., Laffont C. in vitro activity of fusidic acid in combination with various antibiotics against Staphylococcus epidermidis. Pathol Biol (Paris) 1988; 36:621-5.
  • 71. Mouton R.P., Koelman A. The interaction patterns of combined antibacterial agents; experiments with two agar diffusion methods. Chemotherapy 1966; 11:10-26.
  • 72. Simon V.C., Simon M. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters. Scand J Infect Dis 1990; Suppl 72:14-9.
  • 73. Foldes M., Munro R., Sorrell T.C., Shanker S., Toohey M. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcos aureus. J Antimicrob Chemother 1983; 11:21-6.
  • 74. Farber B.F., Yee Y.C., Karchmer A.W. Interaction between rifampicin and fusudic acid against methicillin-resistant coagulase-positive and -negative staphylococci. Antimicrob Agents Chemother 1986; 30:174-5.
  • 75. Uri J.V. Antibacterial antagonism between fusidic acid ciprofloxacin. Acta Microbiol Hung 1993; 40:141-9.
  • 76. Abeck D., Mempel M. Staphylococcos aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139 Suppl 53:13-6.
  • 77. Nordin P., Mobacken H. A comparison of fusidic acid and flucloxacillin in the treatment of skin and soft-tissue infection. Eur J Clin Res 1994; 5:97-106.
  • 78. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989; 20:1083-7.
  • 79. Langdon C.G., Mahaputra K.S. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in acute skin sepsis. Curr Ther Res 1990; 48:174-80.
  • 80. El Mofty M., Harvey S.G., Gibson J.R., Calthrop J.G., Marks P. Trimethoprim-polymyxin B sulphate cream compared with fusidic acid cream in the treatment of superficial bacterial infection of the skin. J Int Med Res 1990; 18:89-93.
  • 81. Somerville D.A., Noble W.C., White P.M., Seville R.H., Savin J.A. Fusidic acid in the treatment of erythrasma. Br J Dermatol 1971; 85:450-3.
  • 82. O’Brien T., McManus F., MacAuley P.H., Ennis J.T. Acute haematogenous osteomyelitis. J Bone Joint Surg (Br) 1982; 64:450-3.
  • 83. Learmonth I.D., Dall G., Pollock D.J. Acute osteomyelitis and septic arthritis in children. A simple approach to traetment. S Afr Med J 1984; 65:117-20.
  • 84. Ernst J. Fucidin treatment of chronic staphylococcal osteitis and osteomyelitis. Acta Orthop Scand 1969; 40:677.
  • 85. Rowling D.E. Further experience in the management of chronic osteomyelitis. J Bone Joint Surg (Br) 1970; 52:302-7.
  • 86. Coombs R.R.H., Mehtar S., Menday A.P. Fusidic acid in orthopaedics. Curr Ther Res Clin Exp 1987; 42:501-8.
  • 87. Learmonth I.D., Dall G., Pollock D.J. Antibiotic therapy in acute infections of bone and joints in children. S Afr Med J 1984; 65:121-2.
  • 88. Perrouin-Verbe B., Poirier P., Touchais S., Richard I., Mathe J.F., Bainvel J.V. Hip sepsis associated with pressure sore in paraplegic patients. Value of one-time surgical treatment. Ann Readapt Med Phys 1994; 37:297-304.
  • 89. Lane-O’Kelly A., Moloney A.C. Acute haematogenous osteomyelitis-evaluation of management in the 1990s. Ir J Med Sci 1995; 164:285-8.
  • 90. Jones N.S., Anderson Dj., Stiles P.J. Osteomyelitis in a general hospital. J Bone Joint Surg (Br) 1987; 69 (Suppl B):779-83.
  • 91. Coombs R.R., Menday A.P. Fusidic acid in orthopaedic infections due to coagulase-negative staphylococci. Curr Med Res Opin 1985; 9:587-90.
  • 92. Mackechnie-Jarvis A.C. Simple wound irrigation system to treat staphylococcal infection of intramedullary nails (letter). Lancet 1985; 1:1035-6.
  • 93. Medcraft J.W., Gardner A.D.H. The use of antibiotic bone cement combination as a different approach to the elimination of infection in total hip replacement. Medlab Technol 1974; 31:347-53.
  • 94. Gransden W.R., Eykyn S.J., Phillips I. Staphylococcus aureus bacteraemis: 400 episodes in St. Thomas’s Hospital. Br Med J (Clin Res Ed) 1984; 288:300-3.
  • 95. Gosden P.E., Reeves B.C., Osborn J.R.S., Turner A., Millar M. Retrospective study of outcome in patients treated for Staphylococcos aureus bacteraemia. Clin Microbiol Infect 1997; 3:32-40.
  • 96. Jackson G., Saunders K. Prosthetic valve diphtheroid endocarditis treated with sodium fusidate and erythromycin. Br Heart J 1973; 35:931-6.
  • 97. Hvidberg J. Fusidic acid in acute conjunctivitis. Single-blind, randomized comparison of fusidic acid and chloramphenicol viscous eye drops. Acta Ophthalmol (Copenh) 1987; 65:4347.
  • 98. Dirdal M. Fucithalmic in acute conjunctivitis. Open, randomized comparison of fusidic acid, chloramphenicol and framycetin eye drops. Acta Ophthalmol (Copenh) 1987; 65:129-33.
  • 99. Tabbara K.F., Antonios S., Alvarez H. Effects of fusidic acid on staphylococcal keratitis. Br J Ophthalmol 1989; 73:136-9.
  • 100. Jensen T., Lanng S., Faber M., Rosdahl V.T., Holby N., Koch C. Clinical experiences with fusidic acid in cystic fibrosis patients. J Antimicrob Chemother 1990; 25: 45-52.
  • 101. Cronberg S., Castor B., Thoren A. Fusidic acid in the treatment of antibiotic associated colitis induced by Clostridium difficile. Infection 1984; 12:276-9.
  • 102. Collignon P., Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12 (Suppl 2):45-58.
  • 103. Jensen K. Methicillin-resistant staphylococci. Lancet 1968; 16:1078.
  • 104. Frlis-Moller A., Rechnitzer C., Nielsen L., Madsen S. Treatment of Legionella lung abscess in a renal transplant recipient with erythromycin and fusidic acid (letter). Eur J Clin Microbiol 1985; 4:513-5.
  • 105. Sorrell T.C., Packham D.R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Fnn Int Med 1982; 97: 344-50.
  • 106. Portier H. A multicenter, open, clinical trial of a new intravenous formulation of fusidic acid in severe staphylococcal infections. J Antimicrob Chemother 1990; 25 (Suppl B):39-44.
  • 107. Cox R.A., Mallaghan C., Conquest C., King J. Epidemic methicillin-resistant Staphylococcus aureus: Controlling the spread outside hospital. J Hosp Inf 1995; 29:107-19.
  • 108. Harris D.M. Clinical implications of methicillin-resistance in Staphylococcos aureus. Guys Hosp Rep 1970; 119:145-54.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились